NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/10/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization787.45 mln
Float15.94 mln
Earnings Date08/04/2026
EPS
19.29
Robust
P / E
2.21
Deeply undervalued
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
1.6
Highly suspicious
1-Year Forecast
54.20
Strong upside
Relative Strength
92
/ 100
Top performer
Business Description
Rigel Pharmaceuticals is a US-based biotech company focused on developing treatments for blood disorders and cancer. Its portfolio includes three approved drugs ? TAVALISSE, REZLIDHIA, and GAVRETO ? targeting conditions such as chronic low platelet counts, a form of leukemia, and certain thyroid and lung cancers. The company is also advancing a new oral drug, R289, through early clinical trials for a range of blood, immune, and inflammatory conditions. Founded in 1996 and based in South San Francisco, Rigel works with leading research institutions, including MD Anderson Cancer Center, to expand the use of its treatments across additional cancer types.
